← Leaderboards
Edward A. Copelan
Northside Hospital Atlanta
$356,975
Attributed
$1,070,925
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $156.3K · FY2017–23$200K$150K$100K$50K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,070,925 · 1
By mechanism
UG1$1,070,925 · 1
Top collaborators
- Asad Bashey7 shared
- Krishna V. Komanduri7 shared
Others in their field
Other Emerging Leaders on “Homologous Transplantation”
- William H. Peranteau · Children'S Hosp Of Philadelphia$4,881,032
- Pietro Genovese · Dana-Farber Cancer Inst$3,626,472
- Harry Karmouty-Quintana · University Of Texas Hlth Sci Ctr Houston$2,925,865
- Heather A Himburg · University Of California Los Angeles$2,438,499
- Nirmala Parajuli · Univ Of Arkansas For Med Scis$2,394,886
- Jessica Diane Weaver · Arizona State University-Tempe Campus$2,355,000
Research focus
Homologous TransplantationImprove AccessHematopoieticHematopoietic Cell TransplantationFutureImmune SystemAntibodiesFamilyBone MarrowExposure ToFollow-UpAllogenicChronic Graft Versus Host DiseaseFailureComorbidityConditioningCostCyclophosphamideDesignDeveloping CountriesDonor PersonAcute Myelocytic LeukemiaCell PhysiologyLymphoid
Grant awards (7)
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$152,051
UG1 · FY2023 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$153,075
UG1 · FY2022 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$154,100
UG1 · FY2021 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$155,199
UG1 · FY2020 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$156,263
UG1 · FY2019 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$149,563
UG1 · FY2018 · HL
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$150,674
UG1 · FY2017 · HL